HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.4%

Neg 0% Neu 90.4% Pos 0%

HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.

Comments

No comments yet. Be the first!